Sign in Subscribe
Biotechnology industries

Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Rights

Strategic Insights

— 1 min read

Kronos Bio Inc, a biotechnology company listed on the Nasdaq under KRON, has entered into a definitive merger agreement to be acquired by Concentra Biosciences LLC for $0.57 in cash per share. The acquisition also includes contingent value rights (CVRs) that entitle shareholders to a portion of future proceeds or cost savings related to Kronos Bio's assets. The eligible assets include product candidates such as KB-9558, KB-7898, KB-0742, lanraplenib, and entospletinib. The Kronos Bio board of directors has unanimously approved the transaction, concluding that it is in the best interest of shareholders after consulting legal and financial advisors.

Key Takeaways:

  • The acquisition price of $0.57 per share represents a premium for Kronos Bio shareholders, with the option to receive up to 100% of proceeds from asset sales completed prior to closing and up to 80% of certain cost savings realized post-closing.
  • The eligible assets for the contingent value rights include product candidates such as KB-9558, KB-7898, KB-0742, lanraplenib, and entospletinib.
  • Shareholders representing approximately 27% of Kronos Bio's stock have agreed to tender their shares and support the merger.
  • A subsidiary of Concentra Biosciences will initiate a tender offer by May 15, 2025, subject to conditions including a majority share tender, at least $40 million in available cash, and other customary closing requirements.
  • The acquisition is expected to close by mid-2025.
  • Concentra Biosciences will acquire Kronos Bio's assets, subject to the terms and conditions outlined in the merger agreement.

Statistics:

  • Acquisition Price: $0.57 per share
  • Amount of proceeds from eligible asset sales: up to 100%
  • Amount of cost savings: up to 80%
  • Shareholders supporting the merger: approximately 27%
  • Tender offer initiation date: May 15, 2025
  • Closing date: expected to be by mid-2025
  • Available cash requirement: at least $40 million
  • Eligible assets: KB-9558, KB-7898, KB-0742, lanraplenib, and entospletinib

Sources:

  • (C)2025 M2 COMMUNICATIONS - http://www.m2.co.uk
  • Nasdaq: KRON - Kronos Bio Inc

Read more